Skip to main content

Table 1 Characteristics of patients

From: Circular stapling anastomosis with indocyanine green fluorescence imaging for cervical esophagogastric anastomosis after thoracoscopic esophagectomy: a propensity score-matched analysis

 

Before matching

 

After matching

 
 

Classical group

ICG circular group

P value

Classical group

ICG circular group

P value

 

(n = 82)

(n = 39)

 

(n = 33)

(n = 33)

 

Age (years)

  

0.892

  

0.872

Median (quartiles)

66 (61–72)

66 (61–71)

 

65 (61–73)

67 (63–73)

 

Sex

  

0.914

  

0.282

 Male

70 (85%)

33 (85%)

 

30 (90%)

27 (82%)

 

 Female

12 (15%)

6 (15%)

 

3 (9%)

6 (18%)

 

Body mass index (kg/m2)

21.2 ± 3.1

22.2 ± 3.3

0.083

21.8 ± 3.1

21.9 ± 3.3

0.677

Serum albumin level (g/dL)

4.2 ± 0.4

4.1 ± 0.4

0.494

4.1 ± 0.4

4.1 ± 0.4

0.985

Brinkman index

  

0.733

  

0.278

Median (quartiles)

800 (445–1000)

860 (435–1000)

 

820 (600–1140)

840 (405–1000)

 

ECOG performance status

  

0.586

  

0.601

 0

68 (83%)

34 (87%)

 

27 (82%)

28 (85%)

 

 1

12 (15%)

5 (13%)

 

5 (15%)

5 (15%)

 

 2

2 (2%)

0 (0%)

 

1 (3%)

0 (0%)

 

Comorbidity

      

 Diabetes

15 (18%)

4 (10%)

0.256

10 (30%)

4 (12%)

0.071

 Cardiovascular disease

10 (12%)

6 (15%)

0.628

2 (6%)

5 (15%)

0.230

 Obstructive ventilation failure

27 (33%)

13 (33%)

0.965

10 (30%)

11 (33%)

0.792

ASA-PS score

  

0.021

  

0.115

 1

11 (13%)

1 (3%)

 

3 (9%)

1 (3%)

 

 2

63 (77%)

28 (72%)

 

27 (82%)

23 (70%)

 

 3

8 (10%)

10 (26%)

 

3 (9%)

9 (27%)

 

Histological type

  

0.009

  

1.000

 Squamous cell carcinoma

78 (95%)

30 (77%)

 

30 (91%)

30 (91%)

 

 Adenocarcinoma

2 (2%)

6 (15%)

 

2 (6%)

2 (6%)

 

 Others

2 (2%)

3 (8%)

 

1 (3%)

1 (3%)

 

Tumor location

  

0.229

  

0.642

 Upper thoracic

11 (13%)

6 (15%)

 

5 (15%)

6 (18%)

 

 Middle thoracic

43 (52%)

16 (41%)

 

15 (46%)

16 (49%)

 

 Lower thoracic

24 (29%)

11 (28%)

 

11 (33%)

7 (21%)

 

 Abdominal

4 (5%)

6 (15%)

 

2 (6%)

4 (12%)

 

cT

  

0.405

  

0.667

 1

36 (44%)

16 (41%)

 

16 (49%)

14 (42%)

 

 2

14 (17%)

11 (28%)

 

5 (15%)

9 (27%)

 

 3

31 (38%)

11 (28%)

 

11 (33%)

9 (27%)

 

 4a

1 (1%)

1 (3%)

 

1 (3%)

1 (3%)

 

cN

  

0.224

  

0.420

 0

44 (54%)

28 (72%)

 

19 (58%)

24 (73%)

 

 1

17 (21%)

5 (13%)

 

7 (21%)

4 (12%)

 

 2

20 (24%)

5 (13%)

 

7 (21%)

5 (15%)

 

 3

1 (1%)

1 (3%)

 

0 (0%)

0 (0%)

 

cStage

  

0.296

  

0.393

 1

32 (39%)

14 (36%)

 

16 (49%)

13 (39%)

 

 2

19 (23%)

14 (36%)

 

5 (15%)

10 (30%)

 

 3

31 (38%)

11 (28%)

 

12 (36%)

10 (30%)

 

Neoadjuvant chemotherapy

  

0.974

  

1.000

 Absent

36 (44%)

17 (44%)

 

16 (49%)

16 (49%)

 

 Present

46 (56%)

22 (56%)

 

17 (52%)

17 (52%)

 
  1. ECOG Eastern Cooperative Oncology Group, ASA-PS American Society of Anesthesiologists physical status